Biotech ETF Deep Dive: Composition, Returns & Investor Fit

Covering: XBI  ·  IBB  ·  ARKG  ·  BBH

Prepared by richstorm.co

Key Takeaways

▸  XBI's equal-weight structure makes it the best ETF for capturing M&A premiums — a small-cap acquisition at 100% premium hits XBI five to seven times harder than it hits market-cap-weighted IBB.

▸  All four ETFs show weak 5-year returns not because biotech is broken, but because the 2021–2023 bear market was severe — entry timing matters enormously in this sector.

▸  IBB offers the most stability through large-cap anchors like Gilead and Vertex, but that same large-cap tilt means it captures little of the small-cap M&A upside driving the sector right now.

▸  ARKG is a high-conviction thematic bet on genomics and gene editing — not a core biotech holding — and its 0.75% fee only makes sense for investors with a specific 5+ year view on CRISPR and AI-driven drug discovery.

▸  Dollar-cost averaging over 12–24 months is the most practical way for retail investors to manage biotech ETF entry timing risk, given the sector's history of 30–65% drawdowns.

WHY BIOTECH ETFS? THE INVESTMENT CASE

For most retail investors, biotech ETFs represent the most practical entry point into small and mid-cap pharmaceutical investing. Individual biotech stock-picking requires scientific expertise, access to clinical trial data, and the stomach to hold through 50-90% binary-event drawdowns. ETFs solve the diversification problem: rather than betting on a single clinical outcome, investors own a basket of companies where the winners compensate for the inevitable failures.

The structural case for biotech ETFs rests on three pillars. First, the M&A tailwind: with $300B+ in big pharma revenue at risk from patent cliffs by 2030 and biotechs responsible for over 70% of new FDA approvals, the acquisition imperative is structural, not cyclical. Second, clinical innovation density: gene editing, ADCs, GLP-1 expansion, and AI-driven drug discovery represent simultaneous waves of innovation concentrated in the small/mid-cap biotech universe. Third, historical long-run performance: despite painful bear markets (2016, 2021-2023), biotech has historically delivered strong 15-20 year compounding returns for patient investors.

This report analyses the four most relevant biotech ETFs for retail investors — XBI, IBB, ARKG, and BBH — covering their composition methodology, top holdings, historical performance across 1-, 5-, and 10-year periods, and a frank assessment of who each fund is right for.

AT-A-GLANCE COMPARISON

HISTORICAL RETURNS VS. S&P 500

All returns are total returns (price appreciation plus reinvested dividends), annualized for 5- and 10-year figures. The S&P 500 benchmark returns are approximately +30% (1-year), +13% CAGR (5-year), and +15% CAGR (10-year) as of April 2026. Color coding: dark green = strong outperformance vs. S&P 500 benchmark, amber = modest shortfall, red = significant laggard.

* ARKG launched October 2014 — 10-year figure reflects since-inception CAGR. BBH restructured from HOLDR format in 2011. All returns approximate as of April 2026 sourced from FinanceCharts, Yahoo Finance, and VanEck SEC filings.

Year-by-Year Return Context

Raw multi-year CAGRs can mask highly variable year-by-year outcomes. The biotech sector experienced a severe bear market from late 2021 through 2023, which is why all four ETFs show weak or negative 5-year CAGRs despite strong trailing 1-year returns.

Key observation: biotech ETFs display extreme annual return volatility compared to the S&P 500. ARKG's +185% in 2020 followed by -50% in 2022 illustrates the asset class's boom-bust character. Investors must size biotech ETF positions with these drawdown magnitudes in mind.

XBI — SPDR S&P BIOTECH ETF

Investment thesis & composition

XBI's equal-weight methodology is its defining characteristic. With ~145 holdings each receiving roughly equal allocation regardless of market cap, a small Phase 3 company gets the same portfolio weight as Gilead Sciences. This structure maximises M&A premium capture — when a small biotech is acquired at a 60–100% premium, XBI feels the full impact. The equal-weight approach also means XBI captures small-cap upside in bull markets but suffers sharper drawdowns during biotech winters. The 5-year CAGR of -3.3% reflects the 2021–2023 biotech bear market; the 2025 recovery drove the strong trailing 1-year return.

Top 5 holdings

Returns at a glance

Strengths

• Maximum M&A premium capture

• broadest small/mid-cap biotech exposure

• ideal for riding structural takeover tailwind

Weaknesses

• Highly volatile

• equal-weight means equal exposure to failures

• 5-year record is negative

• not suitable for conservative investors

Best suited for

Investors who believe in the structural M&A cycle and can tolerate 30-50% drawdowns; best held in a diversified portfolio at 5-10% allocation.

IBB — ISHARES BIOTECHNOLOGY ETF

Investment thesis & composition

IBB is the largest and most liquid biotech ETF, tracking the Nasdaq Biotechnology Index via market-cap weighting. Its top 10 holdings represent approximately 50% of assets, meaning it behaves more like a large-cap biotech fund with small-cap flavoring than a true small/mid-cap vehicle. Gilead, Vertex, and Amgen collectively account for nearly 28% of the fund. While this concentration provides relative stability, it also means IBB captures far less M&A premium from small-cap acquisitions — a small biotech acquired at 100% premium contributes negligibly to IBB's returns. The 10-year CAGR of +4.7% significantly trails the S&P 500's +15%, reflecting the broader biotech underperformance during the 2016–2023 period.

Top 5 holdings

Returns at a glance

Strengths

• Highest liquidity ($7B+ AUM)

• broadest index (380 names)

• most stable biotech ETF

• lowest binary event risk per position

Weaknesses

• Dominated by large-caps

• captures little M&A premium

• 10-year record badly trails S&P 500

• higher expense ratio than XBI

Best suited for

Investors wanting defensive biotech exposure with lower volatility; those more comfortable with large-cap names; complements XBI well in a blended allocation

ARKG — ARK GENOMIC REVOLUTION ETF

Investment thesis & composition

ARKG is the sector's most distinctive active fund, managed by Cathie Wood's ARK Invest with a concentrated portfolio of ~32 holdings focused on the genomics revolution: CRISPR gene editing, DNA sequencing, AI-driven drug discovery, and multiomics. The top 10 holdings comprise approximately 60% of assets — very high concentration for an ETF. ARKG is a thematic bet on a specific wave of innovation rather than broad biotech exposure. Its 2020 peak (+185% that year) reflected the COVID-driven euphoria around genomic technologies; its subsequent -75% peak-to-trough drawdown reflected the reversal. The fund has partially recovered on CRISPR clinical breakthroughs and the broader biotech rally of 2025.

Top 5 holdings

Returns at a glance

Strengths

• Unique genomics/gene-editing exposure not available via passive ETFs

• genuine thematic conviction

• captures CRISPR and AI-bio intersection

Weaknesses

• Highest expense ratio (0.75%)

• very concentrated (32 names, top 10 = 60%)

• enormous drawdown history (-75% peak-to-trough)

• manager dependency risk

Best suited for

Sophisticated investors with 5+ year horizon who want a specific thematic bet on genomics; should be a small satellite position (2-5%) alongside broader biotech exposure

BBH — VANECK BIOTECH ETF

Investment thesis & composition

BBH tracks the MVIS US Listed Biotech 25 Index — a highly concentrated portfolio of only 25 of the most liquid biotech names by market cap. This is the most top-heavy of the major biotech ETFs: its top five holdings often represent 50%+ of the fund, and the top three (Gilead, Vertex, Amgen) account for approximately 38% of assets alone. BBH is better understood as a large-cap biotech fund with 25 names than a true biotech index. The concentration reduces idiosyncratic risk from individual failures but also removes the M&A-driven upside that makes broader biotech ETFs attractive. Its 1-year return of +21.2% significantly trailed XBI (+40.8%) and IBB (+34.0%), reflecting this large-cap tilt during a year driven by small-cap M&A activity.

Top 5 holdings

Returns at a glance

Strengths

• Very low expense ratio (0.35%)

• simple, liquid exposure to the 25 largest biotech names

• lowest volatility of the four ETFs

Weaknesses

• Extreme concentration in top holdings

• captures almost no M&A premium from small-cap deals

• smallest AUM ($365M) — liquidity risk

• 1-year return lagged peers significantly

Best suited for

Investors who want a simple, low-cost proxy for large-cap biotech valuations; not appropriate as a primary vehicle for capturing the small/mid-cap M&A tailwind

STRUCTURAL ANALYSIS — WHY WEIGHTING METHODOLOGY MATTERS MOST

Equal-weight vs. market-cap-weight: the M&A premium difference

The single most important structural difference between XBI and IBB is not their expense ratios or number of holdings — it is their weighting methodology and its implications for M&A premium capture. In an equal-weight fund like XBI, every holding starts at approximately 0.7% of the portfolio. When a small biotech company in XBI is acquired at a 100% premium, XBI captures the full 100% gain on that 0.7% weight — contributing approximately 0.7% to overall fund performance.

In a market-cap-weighted fund like IBB, that same small biotech might represent only 0.1-0.2% of the fund (since Gilead at 9.4% dominates). The 100% acquisition premium contributes only 0.1-0.2% to IBB's performance — five to seven times less impact. Given that small-cap M&A is the primary alpha engine in biotech, this structural difference is the primary reason XBI outperformed IBB by approximately 7 percentage points on a trailing 1-year basis, despite broader sector conditions being identical for both funds.

The concentration risk spectrum

The four ETFs represent a spectrum of concentration risk, from XBI's ~145 equal-weighted holdings to BBH's 25 top-heavy names. The appropriate level of concentration depends on the investor's view:

• XBI (145 equal-weighted): Best for investors who want maximum diversification across the biotech opportunity set, accepting that they will own many failures alongside the big winners. The statistical law of large numbers works in your favor.

• IBB (380 market-cap-weighted): Best for investors who believe large-cap biotech names (Gilead, Vertex, Amgen) will drive sector returns, and want downside protection from established cash-flow-generating companies.

• ARKG (32 conviction-weighted): Best for investors with a specific view on genomics and gene editing as the next generation of pharmaceutical innovation, accepting very high concentration and manager dependency risk.

• BBH (25 large-cap-weighted): Best for investors who want the simplest, most liquid exposure to the largest biotech names, accepting that they are essentially buying a large-cap healthcare fund with biotech labelling.

The 5-year return paradox

All four ETFs show weak or negative 5-year CAGRs despite strong trailing 1-year returns. This is not a contradiction — it reflects the severity of the 2021-2023 biotech bear market. The XBI fell over 65% from its February 2021 peak to its November 2023 trough. Investors who bought in early 2021 at peak valuations are still recovering even after the 2024-2025 rally. This illustrates two critical lessons:

• Entry point matters enormously in biotech: An investor who bought XBI in January 2020 has dramatically better 5-year returns than one who bought in January 2021. Valuations within the biotech sector are mean-reverting and cyclical. Buying during bear markets (2022-2023) has historically been the highest-return entry point.

• Dollar-cost averaging manages entry timing risk: For most retail investors, spreading biotech ETF purchases over 12-24 months rather than investing a lump sum materially reduces entry timing risk. The sector's volatility means a single lump-sum investment at the wrong moment can take 5+ years to recover.

PORTFOLIO CONSTRUCTION — HOW TO USE THESE ETFS TOGETHER

The four ETFs are not mutually exclusive — combining them within a biotech allocation can produce a more balanced risk/return profile than using any single fund. Below are three illustrative model allocations ranging from conservative to aggressive:

* Total biotech allocation as percentage of a diversified equity portfolio. Investors with lower risk tolerance should remain at the lower end. These are illustrative model allocations, not personalised recommendations.

When to consider rebalancing

• After a major biotech rally (+30%+ from trough): Consider trimming XBI/ARKG back to target weights. The equal-weight structure of XBI means the M&A-premium benefit has already been captured; subsequent performance depends more on overall sector sentiment.

• After a major biotech bear market (-30%+ from peak): Consider adding to XBI — historically, entry at deep drawdowns has produced the strongest 3-5 year subsequent returns. The 2022-2023 trough was the best entry point in a decade.

• When holding period exceeds 3 years: Review whether ARKG's active management continues to add value relative to its 0.75% fee. If genomics-specific returns do not materialise within 3-5 years, a passive XBI allocation may be more appropriate.

CONCLUSION

The four biotech ETFs analysed in this report serve different investor purposes, and selecting the right one requires clarity about your investment objectives and risk tolerance — not simply chasing the fund with the best trailing 1-year return.

XBI is the purest expression of the small/mid-cap biotech M&A thesis. Its equal-weight methodology maximises premium capture from acquisitions — the primary alpha driver in the sector over the next 5-10 years, given the patent cliff imperative facing big pharma. It is the most volatile of the four, but also the most aligned with the structural opportunity we have described throughout this research series.

IBB is the most appropriate choice for investors who want broad biotech exposure with the stability of large-cap names anchoring the portfolio. It is the largest, most liquid fund, but its market-cap weighting means it is effectively a large-cap biotech fund — capturing little of the small-cap M&A premium that makes the sector structurally attractive right now.

ARKG is a specific thematic bet on genomics and gene editing. For investors who believe CRISPR therapies, AI-driven drug discovery, and multiomics represent the next pharmaceutical revolution — and who accept the high volatility, high concentration, and manager dependency that comes with Cathie Wood's active management — ARKG provides unique exposure not replicable through passive ETFs. It should be a satellite position, not a core holding.

BBH is the most conservative of the four, essentially providing large-cap biotech exposure in a concentrated 25-name package. Its 1-year underperformance relative to XBI and IBB in 2025 (-21% vs +41% and +34%) illustrates the opportunity cost of excessive large-cap concentration in a year dominated by M&A-driven small-cap returns. It is best used as a small complementary position rather than a primary biotech allocation vehicle.

If you found this analysis useful, RichStorm publishes independent pharma investment research grounded in science. Subscribe free to receive new insights directly in your inbox. [Subscribe here]

Prepared by RichStorm LLC | April 2026 | For informational purposes only. Not investment advice. All information based on publicly available sources. Past performance is not indicative of future results. Readers should consult a qualified financial adviser before making investment decisions.